**Correction to**: *British Journal of Cancer* (2009) **100**, 1926--1936; doi:10.1038/sj.bjc.6605072

In reference to [Figure 4D](#fig4){ref-type="fig"}, the drug quercetin is clearly cytotoxic as a single agent in the ALL-SIL cell line, but its effect in combination with dexamethasone (DEX) is not synergistic as originally quoted. Rather, the combination of quercetin and DEX resulted in a small, though non-significant reduction in cytotoxicity. This is in contrast to resveratrol ([Figure 4E](#fig4){ref-type="fig"}), which demonstrated synergistic cytotoxicity in combination with DEX. This difference in the two agents is reflected in their connectivity map (CMAP) enrichment scores in [Table 3](#tbl3){ref-type="table"}, with quercetin showing a positive enrichment in contrast to the negative scores for resveratrol, LY-294002 and rapamycin. Both quercetin and resveratrol are polyphenols that activate the key metabolic regulator AMPK, but the results suggest that they are mechanistically different and are unlikely to be equally efficacious in combinatorial therapy with glucocorticoids in T-cell acute lymphoblastic leukaemia (T-ALL). [Figure 4D](#fig4){ref-type="fig"} and [Table 3](#tbl3){ref-type="table"} from the original paper are reproduced for reference, below.

![Synergy of CMAP-identified drugs with DEX in T-ALL cell lines. Graphs show cell survival following 48 h incubation. Comparisons were made in each data set to the respective control condition, which was set to 100%. Vehicle control (C) and the following drug treatments were analysed: (D) 10 m[M]{.smallcaps} (Q10), 25 m[M]{.smallcaps} (Q25) quercetin and 1 m[M]{.smallcaps} DEX (D1) in ALL-SIL.](6605632f4){#fig4}
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CMAP drugs significantly associated with MPRED- and DEX-resistance gene signatures in T-ALL cell lines

  **MPRED**        **DEX**                                                                                                             
  ---------------- ------------------------------------ -------- -------- ----------------------- --------------------------- -------- ----------
  LY-294002        AKT/PI3K inhibitor                   −0.507   0.0001   Rapamycin               mTOR inhibitor              −0.653   \<0.0001
  Trichostatin A   HDAC inhibitor                       −0.423   0.018    Geldenamycin            HSP90 inhibitor             0.655    0.004
  Carbamazepine    Antiepileptic                        −0.792   0.020    LY-294002               AKT/PI3K inhibitor          −0.397   0.005
  W-13             Calmodulin antagonist                0.903    0.021    Sodium phenylbutyrate   HDAC inhibitor              −0.564   0.014
  Blebbistatin     Myosin II inhibitor                  −0.896   0.023    Quercetin               ROS scavenger/antioxidant   0.903    0.019
  Wortmannin       AKT/PI3K inhibitor                   −0.497   0.024    Resveratrol             ROS scavenger/antioxidant   −0.630   0.020
  Benserazide      Amino-acid decarboxylase inhibitor   0.885    0.028    Cobalt chloride         Hypoxia mimetic             −0.742   0.037
  Rapamycin        mTOR inhibitor                       −0.441   0.031    Fludrocortisone         Steroid                     0.857    0.042
  Indomethacin     Cyclo-oxygenase inhibitor            0.662    0.031    Deferoxamine            Hypoxia mimetic             −0.717   0.049
  Quercetin        ROS scavenger/antioxidant            0.876    0.033                                                                  
  Y-27632          Rho-kinase inhibitor                 −0.872   0.036                                                                  
  Tamoxifen        Oestrogen-receptor blocker           0.740    0.039                                                                  
  Resveratrol      ROS scavenger/antioxidant            −0.583   0.040                                                                  

Data indicate the CMAP-calculated enrichment score and permuted *P*-value for association with GC expression profiles.
